CHD Church & Dwight
Quality staples compounder, but 34x earnings prices in perfection a 4%-growth business cannot deliver.
The story
Church & Dwight runs a portfolio of niche-leading consumer brands (Arm & Hammer, OxiClean, TheraBreath, Batiste, Hero, Touchland). Its moat is brand strength in categories where it is the number one or two player, plus a lean, asset-light model that grows by buying brands and then gaining distribution. It is a mature, steady compounder: organic growth of 3-4% a year plus bolt-on deals, and it is pruning weaker brands to lift margins.
Reported margins swing because of impairment charges. Underlying margins are about 20%, and recent divestitures plus gross-margin gains justify 21% at steady state. The reported sales-to-capital of 1.0 is weighed down by acquisition goodwill, while capex runs below D&A, so incremental reinvestment of 2.2 is the honest figure. A 10-year horizon fits a durable brand franchise with modest growth. These drivers still value CHD well below the market's roughly 34x earnings, which tells me the price is paying for safety rather than for fundamentals.
Value drivers
| Revenue growth (Y1) | 4.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 21.0% |
| Years to target margin | 5 |
| Sales-to-capital | 2.20 |
| Beta | 0.70 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 7.9% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | 6.97B |
| PV of terminal value | 8.57B |
| Equity value | 13.60B |
| ÷ shares → per share | $57.33 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 6.45B | 4.0% | 17.7% | 877.07M | 112.83M | 764.25M | 708.42M |
| 2 | 6.70B | 3.9% | 18.5% | 954.42M | 114.08M | 840.34M | 722.04M |
| 3 | 6.96B | 3.8% | 19.3% | 1.04B | 115.13M | 920.21M | 732.90M |
| 4 | 7.21B | 3.7% | 20.2% | 1.12B | 115.96M | 1.00B | 741.11M |
| 5 | 7.47B | 3.6% | 21.0% | 1.21B | 116.57M | 1.09B | 746.76M |
| 6 | 7.73B | 3.4% | 21.0% | 1.25B | 116.95M | 1.13B | 718.36M |
| 7 | 7.98B | 3.3% | 21.0% | 1.29B | 117.07M | 1.17B | 690.29M |
| 8 | 8.24B | 3.2% | 21.0% | 1.33B | 116.94M | 1.22B | 662.61M |
| 9 | 8.50B | 3.1% | 21.0% | 1.37B | 116.55M | 1.26B | 635.35M |
| 10 | 8.75B | 3.0% | 21.0% | 1.42B | 115.88M | 1.30B | 608.55M |
Key risks
- Private-label and promotional pressure squeezes pricing in laundry and litter
- Acquisition missteps lead to more write-downs (as with Hero, ZICAM and Flawless)
- Lower volumes as consumers trade down, plus tariff and input-cost inflation
Catalysts
- Portfolio pruning and Touchland integration lift the mix toward higher-growth, higher-margin brands
- International expansion of TheraBreath, Hero and Batiste